Insights from the MAPLE Trial: Clinical Implications for oHCM Management

This episode, titled Insights from the MAPLE Trial: Clinical Implications for oHCM Management, features panelists discussing the following question:

Can you please discuss the MAPLE trial and its clinical implications?

Led by Dr. Maron, Drs. Harper, Le, and Rader examined the MAPLE trial, which provides important comparative data on the efficacy and safety of aficamten versus standard therapy in patients with symptomatic obstructive hypertrophic cardiomyopathy. Findings from the study highlight improvements in hemodynamic parameters, symptom burden, and functional capacity, supporting the role of cardiac myosin inhibition as a targeted treatment approach. The trial also offers insight into how newer therapies may fit into existing treatment algorithms alongside traditional agents. These results have meaningful clinical implications, particularly in guiding personalized treatment decisions and optimizing patient outcomes in real-world practice.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, Invasive Treatment Options in Hypertrophic Cardiomyopathy, panelists will continue their discussion on the role of invasive procedures, such as septal myectomy and alcohol septal ablation, in the management of hypertrophic cardiomyopathy. It highlights patient selection, expected outcomes, and how these interventions fit within the broader treatment landscape.